MAP2K6 and atherosclerosis: Together with the observations of reduced HGF, PDGBF, MAP2K6, and QDPR, these results suggest that the novel Affibody molecule effectively blocks IL17A and attenuates circulating inflammatory markers and other atherosclerosis-associated proteins.